Chinese molecular diagnostics and precision medicine firm GenePlus Technology filed for an IPO on the Hong Kong Stock Exchange, listing precision diagnostics, clinical R&D enablement and AI‑driven omics services as core businesses. GenePlus disclosed 2024 revenue of RMB 557.1 million and significant net losses as it seeks capital to scale clinical and diagnostic products. Separately, Guardant Health’s Guardant360 CDx received Japanese approval as a companion diagnostic for Eli Lilly’s Inluriyo, allowing ESR1 mutation testing to inform therapy selection. The regulatory clearance expands Guardant’s geographic footprint for tumor‑profiling CDx use and supports wider adoption of liquid biopsy tools in oncology. Together these moves underscore ongoing investor interest in diagnostics and the international regulatory momentum for liquid biopsy CDx solutions, both for trial selection and clinical use.